Drug guidance
Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
Condition
Eye
16 September 2025
Published on 02 Jan 2024
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Aflibercept 2 mg/0.05 mL prefilled syringe and vial; and
Faricimab 6 mg/0.05 mL vial
For treating adults with visual impairment due to:
diabetic macular oedema; and
neovascular (wet) age-related macular degeneration.
Funding status
Aflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2025.
Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MAF for the abovementioned indications from 1 March 2024.
MAF assistance does not apply to other formulation(s) or strengths(s) of aflibercept and faricimab for treating diabetic macular oedema or neovascular age-related macular degeneration.